These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

771 related items for PubMed ID: 24052318

  • 1. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
    Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, Floquet A.
    Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
    [Abstract] [Full Text] [Related]

  • 2. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.
    Petrillo M, Ferrandina G, Fagotti A, Vizzielli G, Margariti PA, Pedone AL, Nero C, Fanfani F, Scambia G.
    Ann Surg Oncol; 2013 Nov; 20(12):3955-60. PubMed ID: 23838915
    [Abstract] [Full Text] [Related]

  • 3. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE.
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [Abstract] [Full Text] [Related]

  • 5. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Ren B, Guo W, Chen X.
    J Ovarian Res; 2016 Dec 02; 9(1):85. PubMed ID: 27912779
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A.
    Eur J Cancer; 2011 Sep 02; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [Abstract] [Full Text] [Related]

  • 8. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 02; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 9. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, Sanches S, Guimarães AP, Achatz MI.
    Ann Surg Oncol; 2015 Dec 02; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [Abstract] [Full Text] [Related]

  • 10. Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?
    Kang S, Jong YH, Hwang JH, Lim MC, Seo SS, Yoo CW, Park SY.
    Ann Surg Oncol; 2011 Dec 02; 18(13):3824-7. PubMed ID: 21691879
    [Abstract] [Full Text] [Related]

  • 11. Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?
    Stoeckle E, Boubli B, Floquet A, Brouste V, Sire M, Croce S, Thomas L, Guyon F.
    Eur J Obstet Gynecol Reprod Biol; 2011 Dec 02; 159(2):407-12. PubMed ID: 21835539
    [Abstract] [Full Text] [Related]

  • 12. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M, Vertaková-Krakovská B, Belohorská B, Miskovská V, Helpianska L, Ondrus D, Ondrusová M, Spánik S, Svec J.
    Klin Onkol; 2009 Dec 02; 22(6):273-7. PubMed ID: 20099745
    [Abstract] [Full Text] [Related]

  • 13. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Chen X.
    Arch Gynecol Obstet; 2017 Feb 02; 295(2):451-458. PubMed ID: 27913927
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Tropé CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H.
    Eur J Cancer; 2012 Sep 02; 48(14):2146-54. PubMed ID: 22382201
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H, Huang H, Huang QD, Li Z, Feng YL, Liu JH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec 02; 47(12):928-33. PubMed ID: 23324194
    [Abstract] [Full Text] [Related]

  • 17. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
    Colombo PE, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, Gourgou S, Rouanet P.
    Eur J Surg Oncol; 2009 Feb 02; 35(2):135-43. PubMed ID: 18289825
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR, Zeeneldin AA, Helal AM, Ismail YM, Elsayed AM, Elbassuiony MA, Moneer MM.
    Asian Pac J Cancer Prev; 2015 Feb 02; 16(16):7237-42. PubMed ID: 26514517
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
    Le T, Alshaikh G, Hopkins L, Faught W, Fung MF.
    Ann Surg Oncol; 2006 Dec 02; 13(12):1711-6. PubMed ID: 17009146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.